Phase 1a trial of RG 3039 in volunteers.
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2012
At a glance
- Drugs PF 6687859 (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Pharmacokinetics
- 25 Apr 2012 Positive safety and pharmacokinetics data were reported in a Repligen Corporation media release.
- 25 Apr 2012 Status changed from recruiting to completed, as reported in a Repligen Corporation media release.
- 24 May 2011 New trial record